Anti-HIV-1 Activity of Benzothiadiazine Dioxide | Zendy

Ana Martı́nez | Zendy; Carmen Gil | Zendy; Ana Castro | Zendy; Concepción Pérez | Zendy; Myriam Witvrouw | Zendy; Christophe Pannecouque | Zendy; Jan Balzarini | Zendy; Erik De Clercq | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anti-HIV-1 Activity of Benzothiadiazine Dioxide

Author(s) -

Ana Martı́nez,

Carmen Gil,

Ana Castro,

Concepción Pérez,

Myriam Witvrouw,

Christophe Pannecouque,

Jan Balzarini,

Erik De Clercq

Publication year - 2001

Publication title -

antiviral chemistry and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.919

H-Index - 51

eISSN - 2040-2066

pISSN - 0956-3202

DOI - 10.1177/095632020101200604

Subject(s) - benzothiadiazine , reverse transcriptase , human cytomegalovirus , mechanism of action , biology , nucleoside , nucleotidyltransferase , virology , nucleoside reverse transcriptase inhibitor , reverse transcriptase inhibitor , biological activity , virus , chemistry , antiretroviral therapy , in vitro , biochemistry , viral load , rna , organic chemistry , gene

Antiviral assays carried out on the potent benzothiadiazine dioxide (BTD) human cytomegalovirus (HCMV) inhibitors have led us to find marginal but selective anti-HIV-1 activity. Specific pharmacological studies, such as time of addition experiments and assays on specific viral strains with mutations on its reverse transcriptase, have indicated that BTD compounds act as non-nucleoside reverse transcriptase inhibitors. Theoretical calculations showed a butterfly conformation for the active derivatives that are compatible with their mechanism of action. Therefore, BTD derivatives can be considered as potential lead compounds for the treatment of opportunistic HCMV infections in immunocompromised individuals such as AIDS patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research